Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Genocea Biosciences, Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 59 staff and has a trailing 12-month revenue of around USD$906,000.
Since the stock market crash in March caused by coronavirus, Genocea Biosciences's share price has had significant negative movement.
Its last market close was USD$2.06, which is 3.74% down on its pre-crash value of USD$2.14 and 87.27% up on the lowest point reached during the March crash when the shares fell as low as USD$1.1.
If you had bought USD$1,000 worth of Genocea Biosciences shares at the start of February 2020, those shares would have been worth USD$699.03 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,000.01.
|Latest market close||USD$2.06|
|52-week range||USD$1.1 - USD$5.75|
|50-day moving average||USD$2.384|
|200-day moving average||USD$2.4782|
|Wall St. target price||USD$9.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.376|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-1.90%|
|1 month (2020-10-30)||-0.96%|
|3 months (2020-08-28)||-11.21%|
|6 months (2020-05-29)||-25.36%|
|1 year (2019-11-29)||-17.60%|
|2 years (2018-11-30)||227.09%|
|3 years (2017-11-30)||68.85%|
|5 years (2015-11-30)||-67.81%|
|Gross profit TTM||USD$-26,952,000|
|Return on assets TTM||-49.41%|
|Return on equity TTM||-176.71%|
|Market capitalisation||USD$131.5 million|
TTM: trailing 12 months
There are currently 1.7 million Genocea Biosciences shares held short by investors – that's known as Genocea Biosciences's "short interest". This figure is 46.1% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting Genocea Biosciences shares can be evaluated.
Genocea Biosciences's "short interest ratio" (SIR) is the quantity of Genocea Biosciences shares currently shorted divided by the average quantity of Genocea Biosciences shares traded daily (recently around 512736.07038123). Genocea Biosciences's SIR currently stands at 3.41. In other words for every 100,000 Genocea Biosciences shares traded daily on the market, roughly 3410 shares are currently held short.
However Genocea Biosciences's short interest can also be evaluated against the total number of Genocea Biosciences shares, or, against the total number of tradable Genocea Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genocea Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Genocea Biosciences shares in existence, roughly 30 shares are currently held short) or 0.043% of the tradable shares (for every 100,000 tradable Genocea Biosciences shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genocea Biosciences.
Find out more about how you can short Genocea Biosciences stock.
We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.
Genocea Biosciences's shares were split on a 1:8 basis on 22 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.
Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $1.1 up to $5.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 2.15. This would suggest that Genocea Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.